MAPT and Alzheimer disease: Notably, MID1 expression is elevated in AD tissues, suggesting that resveratrol may be a potential drug to interfere with MID1-PP2A complex-induced tau dephosphorylation and reduce the formation of PHFS and NFTS in AD patients [44].